Disclosures for "Tirzepatide and Reduced Initial Ischemic Stroke Risk in Adults with Type 2 Diabetes: A Target Trial Emulation"
-
Dr. Wang has nothing to disclose.
-
Dr. Faysel has nothing to disclose.
-
Dr. Chiang has nothing to disclose.
-
Dr. Hecht has nothing to disclose.
-
Dr. Levine has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MEDLINK. Dr. Levine has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Law Firms. The institution of Dr. Levine has received research support from NIH.